Results 131 to 140 of about 2,196 (157)

Oxidation hypothesis of atherogenesis: HDL inflammatory index and apolipoprotein A-I mimetic peptides

Future Cardiology, 2007
Coronary heart disease is the leading cause of death in the USA and worldwide. Optimizing the ratio and levels of low- and high-density lipoproteins (HDLs) has been a major focus of treatments in preventing atherosclerosis. While these therapies have made significant contributions in reducing heart disease, many patients with normal lipid levels still ...
Mohamad Navab
exaly   +3 more sources

Apolipoprotein A-I mimetic peptides

Current Opinion in Lipidology, 2010
To review published data related to the potential applicability of apolipoprotein A-I mimetic peptides.Despite a wealth of information on HDL-C levels and risk for cardiovascular disease (CVD), little evidence is present to suggest that raising HDL-C levels per se will result in CVD risk reduction.
G K, Hovingh, Andrea E, Bochem, John J P, Kastelein   +2 more
  +7 more sources

Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention

Nature Clinical Practice Cardiovascular Medicine, 2006
The importance of apolipoprotein A-I (apoA-I) in atherosclerosis was established by testing in animal models, and its potential usefulness in humans has been confirmed in preliminary studies. ApoA-I is a large protein comprising 243 amino acids, which means that venous administration is necessary.
Mohamad, Navab, G M, Anantharamaiah, Srinivasa T, Reddy, Alan M, Fogelman   +3 more
openaire   +2 more sources

Apolipoprotein A-I Mimetic Peptides: Potential Role in Atherosclerosis Management

Trends in Cardiovascular Medicine, 2005
Atherothrombotic vascular disease continues to be a leading cause of morbidity and mortality in much of the world. Although a healthy lifestyle and low-density lipoprotein cholesterol lowering significantly reduce cardiovascular morbidity and mortality, substantial number of adverse vasoocclusive events continue to occur.
Prediman K, Shah, Kuang-Yuh, Chyu
openaire   +2 more sources

Formation of stable nanodiscs by bihelical apolipoprotein A‐I mimetic peptide

Journal of Peptide Science, 2016
Nanodiscs are composed of scaffold protein or peptide such as apolipoprotein A‐I (apoA‐I) and phospholipids. Although peptide‐based nanodiscs have an advantage to modulate the size of nanodiscs by changing phospholipid/peptide ratios, they are usually less stable than apoA‐I‐based nanodiscs. In this study, we designed a novel nanodisc scaffold peptide (
Hirokazu, Kariyazono, Ryo, Nadai, Rin, Miyajima, Yuki, Takechi-Haraya, Teruhiko, Baba, Akira, Shigenaga, Keiichiro, Okuhira, Akira, Otaka, Hiroyuki, Saito   +8 more
openaire   +2 more sources

Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide

International Journal of Cardiology, 2019
Apolipoprotein (Apo)A-I is a major protein component of high-density lipoprotein (HDL) that causes cholesterol efflux from peripheral cells through ATP-binding cassette transporter A1 (ABCA1) and the generation of HDL. Furthermore, it has a possible protective function against atherosclerotic cardiovascular disease (ASCVD).
Yasunori, Suematsu, Emi, Kawachi, Yoshiaki, Idemoto, Yoshino, Matsuo, Takashi, Kuwano, Ken, Kitajima, Satoshi, Imaizumi, Akira, Kawamura, Keijiro, Saku, Yoshinari, Uehara, Shin-Ichiro, Miura   +10 more
openaire   +2 more sources

Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal

Current Opinion in Lipidology, 2004
Recent publications related to the potential use of apolipoprotein (apo)A-I and apoA-I mimetic peptides in the treatment of atherosclerosis are reviewed.A preliminary report indicating that infusion of apoA-IMilano into humans once weekly for 5 weeks caused a significant decrease in coronary artery atheroma volume has sparked great interest in the ...
Mohamad, Navab, G M, Anantharamaiah, Srinivasa T, Reddy, Brian J, Van Lenten, Geeta, Datta, David, Garber, Alan M, Fogelman   +6 more
openaire   +2 more sources

Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia

American Journal of Physiology-Endocrinology and Metabolism, 2012
An apolipoprotein A-I mimetic peptide, D-4F, has been shown to improve vasodilation and inhibit atherosclerosis in hypercholesterolemic low-density lipoprotein receptor-null (LDLr−/−) mice. To study the metabolic variations of D-4F ininhibiting atherosclerosis, metabonomics, a novel system biological strategy to investigate the pathogenesis, was ...
Zhi-Jun, Ou, Li, Li, Xiao-Long, Liao, Yi-Ming, Wang, Xiao-Xia, Hu, Qing-Li, Zhang, Zhi-Ping, Wang, Huan, Yu, Xi, Zhang, Ping, Hu, Ying-Qi, Xu, Qiong-Lin, Liang, Jing-Song, Ou, Guoan, Luo   +13 more
openaire   +2 more sources

Apolipoprotein A-I Mimetic Peptides in Mouse Models of Cancer

2015
Novel therapeutic approaches, free of secondary side effects, are desperately needed for the treatment of cancers especially recurrent, chemotherapy-resistant cancers. It is now established that inflammation and lipoprotein metabolism play an important role in cancer development and progression.
Robin Farias-Eisner, Feng Su, G. M. Anantharamahiah, Mohamad Navab, Alan M. Fogelman, Srinivasa T. Reddy   +5 more
openaire   +1 more source

Apolipoprotein A-I Mimetic Peptide Retains Function After Oxidant Exposure

ASME 2008 Summer Bioengineering Conference, Parts A and B, 2008
Mechanical integrity of arteries is vital for maintaining compensatory mechanisms under physiologic conditions, and changes in vessel structure (and consequently, vessel mechanical properties) are hallmarks of the progression of pathologic states. Oxidative stress can (1) induce endothelial dysfunction by interfering with nitric oxide (NO) signaling ...
Amanda K. Wake, Geeta Datta, Mayakonda N. Palgunachari, Vinod K. Mishra, G. M. Anantharamaiah, C. Roger White   +5 more
openaire   +1 more source